Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.39% |
| 2 | Financials | 6.67% |
| 3 | Healthcare | 6.18% |
| 4 | Industrials | 4.97% |
| 5 | Consumer Discretionary | 4.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3801
Denali Therapeutics
DNLI
$3.67B
| $2.11M | ﹤0.01% |
41,842
+22,399
| +115% | +$1.26M |
|
3802
CRA International
CRAI
$1.16B
| $2.11M | ﹤0.01% |
21,205
-893
| -4% | -$80.6K |
|
|
NBIS
3803
Nebius Group N.V.
NBIS
$54B
| $2.1M | ﹤0.01% |
+26,409
| New | +$1.92M |
|
3804
CALL
UiPath
PATH
$6.76B
| $2.1M | ﹤0.01% |
+40,000
| New | +$2.42M |
|
|
HCAR
3805
DELISTED
Healthcare Services Acquisition Corporation Class A Common Stock
HCAR
| $2.1M | ﹤0.01% |
215,794
+171,342
| +385% | +$1.66M |
|
3806
CarGurus
CARG
$3.33B
| $2.1M | ﹤0.01% |
66,969
-181,402
| -73% | -$5.29M |
|
3807
PUT
Vornado Realty Trust
VNO
$7.51B
| $2.09M | ﹤0.01% |
49,800
+20,000
| +67% | +$862K |
|
|
SLCA
3808
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $2.09M | ﹤0.01% |
261,632
-45,278
| -15% | -$428K |
|
|
ZWRK
3809
DELISTED
Z-Work Acquisition Corp. Class A Common Stock
ZWRK
| $2.09M | ﹤0.01% |
214,573
-30,192
| -12% | -$292K |
|
3810
Cimpress
CMPR
$2.4B
| $2.09M | ﹤0.01% |
24,048
-2,901
| -11% | -$284K |
|
3811
Outlook Therapeutics
OTLK
$171M
| $2.08M | ﹤0.01% |
+48,013
| New | +$2.32M |
|
|
PFDRU
3812
DELISTED
Pathfinder Acquisition Corporation Unit
PFDRU
| $2.08M | ﹤0.01% |
208,000
-577,850
| -74% | -$5.79M |
|
3813
Annovis Bio
ANVS
$73.2M
| $2.08M | ﹤0.01% |
65,619
+62,032
| +1,729% | +$3.57M |
|
|
RAPT
3814
PUT
DELISTED
RAPT Therapeutics
RAPT
| $2.08M | ﹤0.01% |
+8,375
| New | +$2.21M |
|
3815
ACNB Corp
ACNB
$656M
| $2.08M | ﹤0.01% |
74,225
-46,922
| -39% | -$1.32M |
|
3816
Black Diamond Therapeutics
BDTX
$99.7M
| $2.08M | ﹤0.01% |
245,517
-82,641
| -25% | -$816K |
|
3817
Eagle Bancorp
EGBN
$849M
| $2.08M | ﹤0.01% |
36,080
+24,033
| +199% | +$1.35M |
|
|
MITT
3818
TPG Mortgage Investment Trust
MITT
$227M
| $2.08M | ﹤0.01% |
181,538
-123,846
| -41% | -$1.36M |
|
3819
Raymond James Financial
RJF
$34.1B
| $2.08M | ﹤0.01% |
22,488
-69,831
| -76% | -$6.26M |
|
3820
Franklin Resources
BEN
$17.9B
| $2.07M | ﹤0.01% |
69,743
-273,148
| -80% | -$8.52M |
|
3821
Spectral AI
MDAI
$51.2M
| $2.07M | ﹤0.01% |
213,522
-138,902
| -39% | -$1.35M |
|
3822
Tecnoglass Holdings Inc.
TGLS
$2.07B
| $2.07M | ﹤0.01% |
+95,398
| New | +$2.01M |
|
3823
iShares US Telecommunications ETF
IYZ
$1.21B
| $2.07M | ﹤0.01% |
63,851
-270,697
| -81% | -$9.12M |
|
3824
Praxis Precision Medicines
PRAX
$8.52B
| $2.07M | ﹤0.01% |
7,465
+3,377
| +83% | +$916K |
|
3825
Coca-Cola Consolidated
COKE
$12B
| $2.07M | ﹤0.01% |
52,490
+15,510
| +42% | +$617K |
|
Similar funds
Millennium Management's Q3 2021 Portfolio in Review
As of Q3 2021, Millennium Management held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Millennium Management deployed $8.65B of net new capital in Q3 2021, opening 1,244 new positions and adding to 2,720 existing holdings. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M.
By sector, the portfolio is most concentrated in Technology at 7.4% of assets, down from 7.8% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $694M trimmed.
- Millennium Management's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Millennium Management added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Millennium Management's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Millennium Management fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Millennium Management's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Millennium Management opened 1,244 new positions and closed 981 in Q3 2021.
- Millennium Management's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.